Supplementary materials: Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA

<b>These are peer-reviewed supplementary materials for the article '</b><b>Health economic outcomes of switching </b><b>to alemtuzumab from other </b><b>disease-modifying therapies in people </b><b>with multiple sclerosis in the USA</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table 1: </b>Treatment duration of DMT used prior to switching to alemtuzumab (pre-index period). <b>Supplementary Table 2:</b> Average healthcare costs per person at index date (initiation of alemtuzumab).<b>Supplementary Figure 1:</b> Study design.<b>Aim:</b> Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). <b>Patients &amp; methods: </b>Retrospective, observational study of IBM MarketScan claims database. PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December 2019) were identified. “Index” was date of alemtuzumab initiation (prescription filled). <b>Results:</b> The study cohort (n = 341) was primarily female (72%) with mean ± standard deviation) age 45.1 ± 9.5 years. At index, duration of MS was 5.3 ± 2.8 years. HCRU (inpatient/outpatient services), outpatient costs (including MS-specific MRI and emergency room visits) and annualized relapse rate significantly reduced over the 2 years following initiation of alemtuzumab. DMT costs reduced over the same period. <b>Conclusion:</b> Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the USA.

本文为发表于《比较效果研究杂志》（*Journal of Comparative Effectiveness Research*）的论文《美国多发性硬化（multiple sclerosis, MS）患者从其他疾病修正疗法（disease-modifying therapies, DMTs）切换至阿仑单抗（alemtuzumab）的卫生经济学结局》的经同行评议补充材料。补充表1：切换至阿仑单抗前（索引期前）所使用的DMT治疗时长。补充表2：索引日（阿仑单抗起始治疗日）的人均平均医疗费用。补充图1：研究设计。研究目的：明确从其他DMTs切换至阿仑单抗的多发性硬化患者（people with multiple sclerosis, pwMS）的人口统计学特征、临床特点、医疗资源利用（healthcare resource utilization, HCRU）及相关费用情况。患者与方法：本研究为回顾性观察性研究，数据来源于IBM MarketScan索赔数据库（IBM MarketScan Claims Database）。纳入2013年1月1日至2019年12月31日期间既往接受过DMT治疗且起始使用阿仑单抗的MS患者。“索引日”定义为阿仑单抗处方配药的起始治疗日期。研究结果：本研究队列共纳入341例患者，其中女性占比72%，平均年龄为45.1±9.5岁（均值±标准差）。索引日时，患者的MS病程为5.3±2.8年。阿仑单抗起始治疗后的2年内，患者的HCRU（住院/门诊服务）、门诊费用（含针对MS的磁共振成像检查及急诊就诊）及年化复发率均显著降低；同期DMT相关费用亦呈下降趋势。研究结论：基于本项来自美国的队列研究结果，从其他DMTs切换至阿仑单抗用于MS治疗后，可观察到卫生经济学获益与临床获益。